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Induction of Apoptosis in Human Retinoblastoma Cells
by Topoisomerase Inhibitors
Michela Giuliano, Marianna Lauricella, Erasmo Vassallo, Maria Carabilld, Renza Vento,
and Giovanni Tesoriere
PURPOSE. TO examine the apoptotic effect induced in human retinoblastoma Y79 cells by campto-
thecin, etoposide, and amsacrine, to examine the effect of these drugs on the expression of many
apoptosis-related modulators, and to test the antiapoptotic effect exerted by insulin-like growth
factor-I (IGF-I).
METHODS. Morphologic features of apoptosis were demonstrated using acridine orange- ethidium
bromide staining and electron microscopy. DNA fragmentation was determined by means of an in
situ cell detection procedure (TdT-dUTP terminal nick-end labeling [TUNEL]) or by electrophoresis
on agarose gels and was quantified by enzyme-linked immunosorbent assay. The expression of
apoptosis-related modulators was studied by western blot analysis. The processing of latent p53
was examined by means of pulse- chase analysis.
RESULTS. Camptothecin, etoposide, and amsacrine induced apoptosis in Y79 cells in a dose-
dependent manner; camptothecin was the most efficacious compound. The effect, which was
dependent on macromolecular synthesis, appeared after a lag of 8 hours and increased for as long
as 24 hours. It was lower in cells treated with IGF-I, a potent mitogenic factor. Camptothecin and
etoposide increased the p53 level after 4 hours of treatment, before the onset of apoptosis. This
effect seemed to be a consequence of the conversion of latent p53 to one that is transcriptionally
active. The drugs also induced an increase in p53-related proteins, such as p21, Bax, and IGF
binding protein-3 (IGF-BP3), and caused a significant reduction of the Bcl-2 level. The latter effect
was less evident in cells pretreated with IGF-I.
CONCLUSIONS. Topoisomerase inhibitors induce apoptosis in Y79 cells. This event is accompanied by
a decrease in the expression of Bcl-2, a death antagonist, and an increase in that of Bax, a death
agonist. A probable consequence of these modifications is the activation of ICE-like activity with
degradation of poly-(adenosine diphosphate [ADP] ribose)-polymerase. Insulin-like growth factor-I
exerts an antiapoptotic action in Y79 cells, and this function is most likely reduced by the
overexpression of IGF-BP3 that is induced by drug treatment. (Invest Ophthalmol Vis Sci. 1998;39:
1300-1311)
R etinoblastoma is a highly malignant cancer of the retinathat occurs in young children. The tumor, which orig-inates from a primitive neuroectodermal cell,' can be
transmitted as an autosomal dominant trait and occurs in a
nonhereditary, sporadic form (unilateral) and in a hereditary
(bilateral) form. The latter is often associated with additional
neoplasms, such as osteosarcoma or soft-tissue sarcoma.23
Retinoblastoma has been used as a prototypic model for the
study of the genetic determination in cancer. Tumorigenesis is
initiated by the inactivation of both alleles of a tumor-suppres-
sor gene RB-1, which is located on chromosome 13ql4 and
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which encodes a product with growth-suppression activity.
The retinoblastoma gene product, a 105-kDa nuclear phospho-
protein, is expressed ubiquitously in normal mammal cells but
has been absent in all retinoblastomas examined to date.4 The
present study was performed using the well-characterized Y79
human retinoblastoma cell line, in which the RB protein is
completely absent.5 Its deregulated proliferation is supported
by a mitogenic loop that is dependent on insulin-like growth
factor-I (IGF-I) and the type I IGF receptor (IGF-IR).6
Apoptosis, or programmed cell death, is a genetically
determined process that has a significant role in the develop-
ment of normal tissues. The process is characterized by mor-
phologic and biochemical modifications consisting of cell
shrinkage, membrane blebbing, chromatin condensation, and
the internucleosomal degradation of DNA.7 It is well known
that ionizing radiation and many chemotherapeutic agents that
are capable of inducing DNA damage exert a specific cytotox-
icity on actively proliferating cells. This cytotoxic effect has
now been attributed to the induction of apoptosis.
Several new chemotherapeutic agents that show promise
in the treatment of many forms of advanced cancer have
recently been adopted for use in the clinic. These drugs in-
clude inhibitors of topoisomerase I, in particular camptothecin
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and its analogs.8 Camptothecin is a plant alkaloid that stabilizes
topoisomerase I-DNA cleavable complexes.9 It inhibits synthe-
sis of DNA and RNA1011 and is capable of inducing apoptosis
and fragmentation of DNA in many cancer cells.1213 An effec-
tive apoptotic action has also been demonstrated in many
systems with the use of etoposide, an agent that inhibits topo-
isomerase II activity by stabilizing a covalent enzyme-DNA
intermediate.14'16
The tumor-suppressor protein p53 exerts an arresting ef-
fect on the Gl stage of the cell cycle, and there is now
increasing evidence that this protein may also induce apopto-
sis.17 More specifically, a substantial increase in the total p53
level is required for the efficient activation of apoptosis after
treatment with chemotherapeutic compounds or irradiation.18
It has also been reported that another tumor-suppressor pro-
tein pRB may, on the contrary, inhibit programmed cell death
and that inactivation of pRB results in apoptosis, which is
mediated by the presence of functional p5319'20 The observa-
tion that pRB is absent in Y79 cells suggested to us that these
cells, when treated with compounds capable of damaging
DNA, may undergo programmed cell death through involve-
ment of the p53 protein.
Despite the interest in this subject, only a few studies have
been produced regarding apoptosis in retinoblastoma cells. In
particular, Inomata et al.2' examined the induction of apopto-
sis in cultured retinoblastoma cells by diverse drugs and they
showed that only okadaic acid, an inhibitor of protein phos-
phatases, is capable of inducing DNA fragmentation in all of the
cell lines tested. Also, sodium butyrate, a compound already
known as an inducer of differentiation in Y79 cells,22 has been
reported to induce apoptosis in these cells.23
The present studies were carried out to assess the poten-
tial apoptotic effect of topoisomerase inhibitors in Y79 cells. In
our findings, camptothecin and etoposide induced apoptotic
fragmentation of DNA and cell death. Moreover, we analyzed
the effects exerted by these compounds on the level of many
apoptosis-related modulators, and we demonstrated that they
favor the conversion of the latent form of p53 to one that is
transcriptionally active. This event was accompanied by an
increased expression of the transcriptional targets of p53.
Finally, our report provides evidence of the antiapoptotic role
exerted by IGF-I in Y79 cells.
METHODS
Cell Culture
The human retinoblastoma Y79 cell line used in this study was
a kind gift from Adriana Albini Gstituto Nazionale per la Ricerca
sul Cancro, Genova, Italy). Cells were grown in suspension in
RPMI-1640 medium, supplemented with 10% heat-inactivated
fetal calf serum and 1% pen-strep, in 75-cm2 tissue culture
flasks (Falcon, Cockeysville, MD) at 37°C in a moist atmo-
sphere of 95% air-5% CO2. The cultures were fed every other
day. For monolayer cultures, 5 X 104 Y79 cells were seeded on
96-well culture plates (1.5 X 105 cells/cm2) precoated with 5
/xg/cm2 poly-i>lysine (MWt 150,000-300,000) and cultured for
24 hours in 200 jxl of serum-free medium consisting of a 2:1
mixture of Dulbecco's modified Eagle's medium (DMEM) and
Ham's F12 medium supplemented with 5 ju.g/ml transferrin, 5
ng/ml sodium selenite, 10 mM HEPES, and 28 mM NaHCO3 (pH
7.2-7.4). The drugs were added, and the incubation was pro-
tracted for the time indicated in the Results section. Topoisom-
erase inliibitors were dissolved in dimethyl sulfoxide and di-
luted to final concentrations in culture medium. Final
concentrations of dimethyl sulfoxide never exceeded 0.04%
and in routine control, exposure had no discernible effect in
Y79 cells.
For the trypan blue exclusion assay, cells were removed
from the wells after drug treatment, pelleted at 300g for 10
minutes and resuspended in phosphate-buffered saline (PBS). A
0.4% solution of trypan blue was added to the cells and the
trypan blue-stained cells were counted with the aid of a he-
mocytometer.
Cell viability was also determined by 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, St.
Louis, MO) colorimetric assay,24 as previously described.6 Mi-
tochondrial dehydrogenases reduce MTT dye to a purple
formazan. The direct proportion between dye reduction and
cell number extends from 1 X 103 to 5 X 105 cells/well. Four
experiments were performed using the MTT assay to deter-
mine cell viability.
The determination of cloning efficiency was performed
under the conditions described by Jarvis et al.25 Pelleted cells
were seeded in 6-well culture plates (400 cells/well in 2 ml
medium) and formation of colonies, defined as clusters of 50
cells or more, was scored after 10 days of incubation. The
experiment was performed three times. All of the media and
the chemical reagents for cell culture were from Sigma (St.
Louis, MO).
DNA Synthesis
To quantify thymidine incorporation into acid-insoluble frac-
tion, 0.5 juCi/well 3H-thymidine (6.7 Ci per millimole; DuPont
NEN, Boston, MA) was added to monolayer cultures, prepared
as reported earlier.6 Cells were labeled for 1 hour at 37 °C, then
harvested and rinsed with PBS. Preparation of trichloroacetic
acid-insoluble fractions and measurement of radioactivity were
performed as previously described.26
Quantification of DNA Fragmentation
Apoptosis was quantified using an enzyme-linked immunosor-
bent assay kit (ELISA; Boehringer Mannhein, Darmstadt, Ger-
many) that measures the amounts of mono- and oligonucleo-
somes produced as a consequence of DNA fragmentation in
the cytoplasmic fraction of lysed cells.2728 Cells, cultured in
monolayers in serum-free medium, were collected and lysed
according to the manufacturer's instructions. After centrifuga-
tion at 20,000,g for 15 minutes, equal amounts of cytosolic
fraction (0.3 /Ltg protein) were applied to ELISA plates, which
were coated with the capture antihistone monoclonal antibody
(mAb; clone HI 1-4). After incubation for 90 minutes at room
temperature and washing, anti-DNA conjugated with horserad-
ish peroxidase was added, and the plates were incubated for
another 90 minutes at room temperature. Visualization was
achieved by addition of the substrate 2,2'-azino-di-(3-ethylbenz-
thiazoline sulfonate) (ABTS). Optical density of the plates was
read at 405 nm (test wave length) and at 490 nm (reference
wave length). Quantitative values, reported as nucleosomal
enrichment, were calculated as the ratio between the absor-
bance measured for drug-treated cells and that measured for
control cells. Results are the mean values recorded in four
experiments.
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933207/ on 12/05/2018
1302 Giuliano et al. IOVS, July 1998, Vol. 39, No. 8
Acridine Orange-Ethidium Bromide Staining
Monolayer cultures in 96-well plates were used in the morpho-
logic studies. After removal of the medium, the cells were
rinsed and treated with a solution composed of 100 /xg/ml
acridine orange plus 100 /xg/ml ethidium bromide. This pro-
cedure allows dead cells to be distinguished from viable cells.
Acridine orange is taken up by living and dead cells and is
intercalated into DNA, turning it green. Ethidium bromide is
taken up only by nonviable cells and turns DNA orange, be-
cause ethidium staining predominates over acridine. Thus,
viable cells appear green and dead cells have bright orange
chromatin. After staining, cells were examined by fluorescence
microscopy and photographed (Kodak Gold Royal 1000 ASA;
Kodak, Rochester, NY) .
Electron Microscopy
Ultrastructural analysis of morphologic changes for evidence of
apoptosis were performed on specimens fixed with 2.5% glu-
taraldehyde in 0.1 M PBS (pH 7.3) for 1 to 2 hours, rinsed twice
in PBS, and postfixed in 1% osmium tetroxide. The cells were
rinsed in PBS, dehydrated through a series of graded alcohols,
embedded in epoxy resin (Epon 812), and polymerized at 60°C
overnight. Semithin sections (0.5 /xm) were mounted on slides
and stained with warm methylene blue. Screening and photog-
raphy were performed using a Zeiss microscope. Ultrathin
sections (100 nm) were mounted on nickel grids and counter-
stained with uranyl acetate for 10 minutes and lead acetate for
1 to 2 minutes. The specimens were processed conventionally
and analyzed by electron microscope (model 1220; JEOL, Lon-
don, UK).
In Situ Cell Death Detection
To detect apoptotic DNA fragments, a kit (Boehringer Mann-
heim) was used for in situ cell death detection by TdT-dUTP
terminal nick-end labeling (TUNEL). After the indication of
Gavrieli et al.,29 3' ends of DNA fragments were labeled with
terminal deoxynucleotidyl transferase (TdT) and fluorescein-
labeled deoxyuridine triphosphate (dUTP). Incorporated fluo-
rescein was detected by an antifluorescein antibody conju-
gated with alkaline phosphatase. After substrate reaction,
stained cells were analyzed under light microscope. Morpho-
logic experiments were repeated four to six times, and typical
data are presented.
DNA Fragmentation Analysis
Y79 cells (107) were lysed in 1 ml buffer consisting of 10 niM
EDTA, 50 mM Tris-HCl (pH 8.0), and 0.5% (wt/vol) TV-lauroyl-
sarcosine and incubated at 50°C for 1 hour with 125 /xg/ml
proteinase K and for 1 hour with 125 /xg/ml RNase. DNA was
extracted according to Martin et al.30 Electrophoresis of 15 /xg
fragmented DNA was carried out on 1.5% agarose gels contain-
ing 0.5 /xg/ml ethidium bromide. The DNA marker was a
123-bp DNA ladder (Sigma).
Western Blot Analysis
Cells were lysed for 30 minutes at 4°C with a solution (15
/xl/106 cells) composed of 1% NP-40, 0.5% sodium deoxy-
cholate, 0.1% sodium dodecyl sulfate (SDS) in PBS (pH 7.4) and
were sonicated three times for 10 seconds (Soniprep 150;
MSE). Proteinase inhibitors were added as follows: 25 /xg/ml
aprotinin, 1 mM phenylmethylsulfonyl fluoride, 10 mM sodium
ortovanadate, 10 mM NaF, 25 /xg/ml leupeptin, and 0.2 mM
sodium pyrophosphate. Cell lysates were centrifuged at
15,000g for 20 minutes at 4°C. Equivalent amounts of protein
(40 /xg) were submitted to sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE). After electrophoretic
transfer to nitrocellulose, proteins were immunoreacted for 2
hours with primary antibodies, then incubated for 30 minutes
with secondary antibodies conjugated with alkaline phospha-
tase, final concentration 330 ng/ml (Promega, Madison, WT).
The primary antibodies were: 1 jag/ml (final concentration)
mouse monoclonal anti-human p53 DO-1 (Santa Cruz Biotech-
nology, Santa Cruz, CA); 10 /xg/ml PAb421 and 5 /xg/ml
PAb240, p53 monoclonal antibodies (Calbiochem, La Jolla,
CA); 2 /xg/ml mouse monoclonal anti-human p21, 1 /xg/ml
mouse monoclonal anti-human Bcl-2, 1 /xg/ml goat polyclonal
anti-human Bax, and 2 /xg/ml goat polyclonal anti-human IGF-
BP3 (all from Santa Cruz Biotechnology); and 5 /xg/ml rabbit
polyclonal anti-human poly<adenosine diphosphate ribose)-
polymerase (PARP; Boehringer Mannheim, Germany). Visual-
ization was performed using nitro blue tetrazolium and bromo-
chloroindoyl-phosphate. p53 and Bcl-2 bands obtained from
western blots were quantified by densitometric analysis. Ex-
periments using western blot analysis were repeated four to six
times, and typical data are presented.
Pulse-Chase Analysis
For these experiments, a monolayer of Y79 cells (6 X 106cells/
well) was seeded in serum-free medium on 6-well culture
plates. After preincubation for 1 hour in methionine- and cys-
teine-free medium, cells were labeled for another hour with
100 /xCi/ml 35S-methionine and 355-cysteine (355 trans-label;
ICN, Aurora, OH) in 0.75 ml methionine- and cysteine-free
medium and then chased for different times in complete me-
dium. Finally, cells were washed with cold PBS, disrupted in
0.5 ml lysis buffer (1% Triton X-100, 100 mM NaCl, 50 mM
Tris-HCl [pH 7.5], 1% aprotinin, 1 mM phenylmethylsulfonyl
fluoride, and 10 /xg/ml leupeptin) and after 30 minutes on ice,
centrifuged at 30,000g. Cell lysates, normalized to 1 mg/ml
protein, were preabsorbed with protein A Sepharose (Santa
Cruz Biotechnology, Santa Cruz, CA). Then, 0.5 /xg/ml DO-1 or
1 /xg/ml PAb421 and protein A Sepharose were added. After 1
hour on ice, the immunoprecipitar.es obtained were washed
with lysis buffer and submitted to 10% SDS-PAGE. Finally, the
gels were fixed for 30 minutes in 7% acetic acid- 0.5% glycerol,
dried in an Easy-Breeze Cell Dryer (Genenco M. Medical,
Firenze, Italy) and then exposed to film (Hyperfilm-MP; Amer-
sham, Buckinghamshire, UK) for autoradiography in the pres-
ence of an intensifying screen at — 70°C for 1 week.
RESULTS
Induction of Apoptosis in Y79 Cells by
Topoisomerase Inhibitors
In our experiments, we evaluated the effect of topoisomerase
inhibitors on the viability of human retinoblastoma Y79 cells.
In Figure 1, results are shown of experiments in which Y79
cells were treated with 2 /xM camptothecin for different peri-
ods. The number of cells decreased progressively as time
passed and was reduced by approximately 40% after 12 hours
and by 84% after 24 hours of incubation. No viable cells were
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FIGURE 1. Effect of camptothecin on cell number (A), DNA synthesis ( • ) , and apoptosis ( • )
in Y79 cells. Cells (5 X 10") were cultured with 2 /xM camptothecin for different periods. After
incubation, cell number was evaluated by means of a 3-(4,5-dimethylthiazol-2-yl)-2,5diphe-
nyltetrazolium bromide colorimetric assay (MTT), DNA synthesis was determined by measur-
ing 3H-thymidine incorporation into an acid-insoluble fraction, and apoptosis was evaluated by
measuring DNA fragmentation with an enzyme-linked immunosorbent assay, as reported in the
Methods section. Data are means ± SEM of four experiments.
detected by light microscopy (trypan blue exclusion assay)
after treatment for three days with 2 jiiM camptothecin. Results
of a viability test, performed by MTT assay, agreed with this
observation. Treatment of Y79 cells with camptothecin re-
sulted in a loss of clonogenicity, which correlated with a
reduction in number of cells. Cloning efficiency, tested by an
assay of colony formation, was equal to 20% of control cloning
efficiency after 12 hours of incubation and to 10% after 24
hours (not shown).
Reduction of the number of cells was a consequence
of the inhibition of cell proliferation and the induction
of apoptosis. The two effects, however, were not simul-
taneous, as is suggested in Figure 1. DNA synthesis, mea-
sured by 3H-thymidine incorporated into acid-insoluble
fraction, declined rapidly during the first 4 hours of treat-
ment, whereas the rate of apoptosis, assessed by an EL1SA
procedure that quantified DNA fragmentation, did not
increase significantly in the first 8 hours of incubation.
Thereafter, apoptosis increased progressively with passing
time, reaching a value at 24 hours that was seven times
greater than that measured at the beginning of incuba-
tion.
w/o






FIGURE 2. Apoptosis induced in Y79 cells that have been treated for 24 hours with topoisomerase inhibitors. (A) Comparison
between the relative efficacy of different topoisomerase inhibitors. (B) Dose-dependent effect induced by camptothecin in cells
that were cultured in serum-free medium without (w/o; • ) or with ( • ) 10 ng/ml insulin-like growth factor-I. Data are means ±
SEM of four experiments.
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FIGURE 3- Induction of internucleosomal DNA fragmentation
by topoisomerase inhibitors. DNA was extracted from the cells
and analyzed by 1.5% agarose gel electrophoresis in the pres-
ence of ethidium bromide staining, as reported in the Methods
section. DNA is shown from control cells (Jane 2) and from
cells treated for 24 hours with 2 fiM camptothecin (lane 3) or
5 /uM etoposide (lane 4). A 123-bp DNA ladder was used as a
marker (lane /).
The apoptotic effect induced in Y79 cells by topoisomer-
ase inhibitors was dose dependent. A comparison between the
relative efficacy of topoisomerase inhibitors (Fig. 2A) shows a
fourfold increase in DNA fragmentation after 24 hours of incu-
bation with 0.5 fiM camptothecin; the same effect was ob-
served with 3 /xM etoposide or 6 jdVl amsacrine. Maximum
induction (sevenfold increase) was elicited by 2 fM campto-
thecin (Fig. 2B).
Recently,6 we demonstrated that Y79 cells produce IGF-I
and IGF-11 and contain the IGF-IR. The growth of these cells
depends on an autocrine mechanism supported by IGFs and
IGF-IR. In this study, we sought to establish whether treatment
of cells with IGF-I could reduce the apoptotic effect exerted by
camptothecin and etoposide. The apoptotic effect of campto-
thecin was less evident in cells pretreated for 24 hours with 10
ng/ml IGF-I (Fig. 2B), particularly at the lowest concentration
of the drug. The antiapoptotic influence of IGF-I was also
evident when etoposide was used to induce apoptosis (not
shown).
Oligonucleosomal fragmentation was also demonstrated
using agarose gel electrophoresis, which showed laddering of
DNA from cells treated for 24 hours with camptothecin or
etoposide, whereas laddering was absent in the untreated con-
trol cells (Fig. 3).
The morphologic features of apoptosis are described in
Figure 4. The presence of condensed, crescent-shaped chro-
matin associated with nuclear membrane was detected by light
microscopy and transmission electron microscopy.
A morphologic analysis was also performed by staining the
cells with acridine orange-ethidium bromide (Fig. 5A). After
this procedure, apoptotic cells were identified by the presence
of nuclei with condensed or fragmented chromatin, a typical
feature of apoptotic cells. This aspect was found in viable
(green stained) and dead cells (orange stained). Exposure of
the cells for 24 hours to 0.5 /xM camptothecin, the concentra-
tion that induced a fourfold increase in DNA fragmentation
(Fig. 2A), caused the death of approximately 40% of cells (not
shown). Moreover, it was observed that when the cells were
exposed to 2 fiM camptothecin, the concentration that caused
a sevenfold increase in DNA fragmentation, approximately 70%
of cells appeared apoptotic when stained with acridine orange
(Fig. 5A). These observations suggest that DNA fragmentation
was associated with an increased number of cells exhibiting
morphologic features of apoptosis.
The fragmentation of DNA in cultured Y79 cells was also
detected by TUNEL assay. This assay labels the 3'-OH ends of
DNA that result from the endonucleolytic cleavage that occurs
during apoptosis. Y79 cells cultured without drugs were
TUNEL negative (Fig. 5B). In contrast, large populations of cells
treated for 24 hours with 2 /xM camptothecin or 5 /xM etopo-
side were TUNEL positive.
Effect of Actinomycin D and Cycloheximide on
Apoptosis Induced by Topoisomerase Inhibitors
The apoptotic effect exerted by topoisomerase inhibitors was
dependent on mRNA and protein synthesis. Increasing the
concentration of actinomycin D, a transcription inhibitor, or
that of cycloheximide, a translation inhibitor, reduced the
apoptotic effect exerted by topoisomerase inhibitors. At a
concentration of 5 jxM, actinomycin D and cycloheximide both
provided Y79 cells with complete protection against cell death
caused by camptothecin (Fig. 6) or etoposide (not shown).
Effect of Topoisomerase Inhibitors on the Levels
of p53, p53-Related Proteins, and Bcl-2
To examine the impact of topoisomerase inhibitors on p53, we
evaluated the level of the protein in Y79 cell extracts by means
of western blot analysis, using three antibodies: DO-1, specific
for the amino-terminal domain; PAb421, specific for the car-
boxyl-terminal regulatory domain; and PAb240, which reacts
with an epitope (residues 212-217) present at the DNA-bind-
ing domain. When DO-1 was used (Fig. 7A) the level of a
protein component with the relative mobility of p53 increased
in cells treated for 24 hours with amsacrine (lane 2) or etopo-
side (lane 3). With 2 p,M camptothecin, the most efficacious
compound, the level of p53 increased by 70% after 4 hours of
incubation (lane 4), reached an increase of 150% after 8 hours
of incubation (lane 5), and attained its maximum level
(+200%) after 24 hours (lane 6). A comparison between the
time dependence of the effects exerted by camptothecin on
apoptosis and on the p53 level (Fig. 7C) caused us to conclude
that the increase in p53 preceded the increase in apoptosis.
The effect of camptothecin on the level of p53 was dose
dependent and at 2 /xM, reached levels three times greater than
levels in untreated control cells (Fig. 7B). With etoposide, the
effect on p53 level was also dose and time dependent (not
shown). When PAb421 (Fig. 7D) or PAb240 (Fig. 7E) antibod-
ies were used for analysis, the level of p53 was not modified
after treatment of the cells with camptothecin or etoposide.
It is well known that p53 activates the transcription of
various genes, including p21waf-l, Bax, and the gene for
IGF-BP3.31 Through the production of these proteins, p53
exerts its functions: p21 is responsible for the antiproliferative
effect of p53 and transcriptional activation of Bax, and IGF-BP3
is associated with the induction of apoptosis.
Western blot analysis showed that after 24 hours of treat-
ment with camptothecin, the level of p21, Bax, and 1GF-BP3
markedly increased (Fig. 8). When the cells were treated with
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FIGURE 4. Cytologic profiles of Y79 cells treated with camptothecin. Y79 cells were cultured for 24 hours with 2 fxM
caniptothecin. Homogeneous hemilunar marginations, typical of apoptosis, were observed in treated cells. In light microscopy, the
crescent is indicated by an arrow, LM, light microscopy (original magnification, X100); TEM, transmission electron microscopy
(original magnification, X 10,000).
etoposide, a similar effect was observed, but it was less evident
than the effect of camptothecin (not shown).
The proteolytic cleavage of PARP, assured by ICE-like
protease activity, is considered a biochemical marker of apo-
ptosis.32 Figure 8 illustrates that treatment of Y79 cells with 2
/xM camptothecin induces proteolysis of PARP (116 kDa) with
the concomitant generation of an 85-kDa fragment. A similar
result was obtained with cells treated with etoposide.
It has been reported that members of the Bcl-2 family
control cell survival by exerting a protective effect against
apoptosis.3334 We demonstrated, by means of western blot
analysis, that topoisomerase inhibitors decreased the level of
Bcl-2 in Y79 cells. The effect was dose dependent (not shown).
The level of Bct-2, which appeared unmodified after 4 hours of
incubation with 2 /xM camptothecin, decreased by 55% after 8
hours and by 73% after 24 hours (Fig. 9A). Similar results were
obtained when the cells were treated with 5 /xM etoposide
(not shown).
We investigated whether the antiapoptotic effect of IGF-I
modifies the action of camptothecin on the expression of the
apoptosis modulators analyzed in the study. When Y79 cells
were pretreated for 24 hours with IGF-I, camptothecin induced
the same marked increases in p53, p21, and IGF-BP3 (not
shown) as occurred in the absence of IGF-I, Instead, effect of
camptothecin or etoposide in decreasing the level of Bcl-2 was
much reduced when the cells were pretreated with IGF-1
(Fig. 9B).
Stimulation by Topoisomerase Inhibitors of the
Processing of p53 Protein
The influence of cycloheximide on the effect exerted by camp-
tothecin and etoposide on p53 level was analyzed by means of
western blot analysis. The analysis was performed by using the
previously described DO-1, which is specific for the ami no-
terminal domain, as the primary antibody (Fig. 10). When Y79
cells were cultured in the presence of 5 yM cyclolieximide for
24 hours, the level of p53 declined to 25% (lane 2) of the value
measured in control cells (lane 1). Twenty-four hours of incu-
bation with caniptothecin or etoposide to Y79 cells increased
the level of p53 by 200% (lane 3) and 180% (lane 5), respec-
tively, compared with the control value. When cyclolieximide
was added with caniptothecin or etoposide, the effect exerted
by these compounds on p53 diminished, but the level of the
protein remained much higher than that in control cells—
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FIGURE 5. Morphologic analysis of Y79 cells cultured in the
presence of topoisomerase inhibitors. (A) Cells stained with an
acridine orange- ethidium bromide fluorescent dye and photo-
graphed under fluorescence microscope. (B) Cells processed
for TdT-dUTP terminal nick-end labeling (TUNEL) and photo-
graphed under light microscope. Control cells (a in A and B)
and cells cultured for 24 hours with 2 JXM camptothecin (b in
A and B) or 5 JLIM etoposide (c in B).
5 10
Inhibitors concentration (uM)
FIGURE 6. Inhibitory effects of actinomycin D and cyclohexi-
mide on apoptosis induced by camptothecin in Y79 cells. Cells
were incubated for 24 hours with 2 /xM camptothecin together
with increasing concentrations of actinomycin D ( • ) or cyclo-
heximide (D). DNA fragmentation was measured by means of
an enzyme-linked immunosorbent assay, as reported in the
Methods section. Data are means ± SEM of four experiments.
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FIGURE 7. Induction of p53 by topoisomerase inhibitors in
Y79 cells. Extracts were prepared from cells treated with
topoisomerase inhibitors. As reported in the Methods section,
identical amounts of protein (approximately 40 /xg) were used
for western blot analysis, using DO-1 (A, B), PAb421 (D), or
PAb240 (E) antibodies. (A) Control cells (lane 7); cells treated
for 24 hours with 10 jaM amsacrine (lane 2) or 5 jitM etoposide
(lane 3); and cells treated for 4 hours (lane 4), 8 hours (lane
5), or 24 hours (lane 6) with 2 /iM camptothecin. (B) Control
cells (lane 7) and cells treated with various concentrations of
camptothecin: 0.5 uM (lane 2), 1 fxM (lane 3), 2 JLLM (lane 4),
or 10 fjM (lane 5). (C) Time-dependent induction of p53 by 2
JJM camptothecin in comparison with the effect exerted on
apoptosis. p53 bands obtained from western blots using DO-1
antibody were quantified by densitometric analysis; p53 level
at time 0 was considered to be 1. (D, E) Control cells (lane 7)
and cells treated for 24 hours with 2 /xM camptothecin (lane 2)
or 5 /xM etoposide (lane 3).
110% (lane 4) and 105% (lane 6) of the control value, respec-
tively. These results indicate that topoisomerase inhibitors
stimulated the production of an immunodetectable form of
p53 from a latent from, by means of different mechanisms,
which are either dependent or independent of synthesis of
new protein.
In an attempt to determine the mechanisms of the in-
crease in p53 content mediated by camptothecin and etopo-
side, we performed a pulse-chase experiment (Fig. 11). Y79
cells, cultured in serum-free medium, were starved for 1 hour
in methionine- and cysteine-free medium and then pulse-la-
beled for 1 hour with 35S-methionine and 35S-cysteine. After
washing, the cells were fed with fresh medium and incubated
in the presence or absence of camptothecin or etoposide for 0,
5, 10, 15, or 24 hours. Finally, labeled p53 was immunopre-
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FIGURE 8. Effect of camptothecin treatment in Y79 cells on
the expression of p21, Bax, and insulin-like growth factor-
binding protein-3 0GF-BP3) and on the degradation of poly-
(adenosine diphosphate ribose>polymerase (PARP). Cells were
incubated for 24 hours in the presence of camptothecin. At the
end, cell extracts were prepared, and identical amounts of
protein (40 /xg) were used for western blot analysis. Shown are
control cells (lane /) and cells treated with 0.5 fiM (lane 2) or
2 jmM (lane 3) camptothecin.
cipitated by DO-1, which reacts with an epitope (residues
37-45) present in human wild-type and mutant p53 at the
amino-terminal transactivation domain. The immunoprecipi-
tate was subjected to SDS-PAGE and detected by autoradiog-
raphy. The relative intensities of the p53 bands determined by
densitometric analysis are reported in Figure 11D. The half-life
of p53 in cells cultured without drugs was calculated to be
approximately 8 hours (Fig. 11 A). When the cells were incu-
bated with 2 JULM camptothecin (Fig, 11B) or 5 JUM etoposide
(data not shown), the level of radioactive p53 increased during
the first 10 hours of the chase period (120%). This effect could
be the result of the processing of p53, which exposed the
epitope to the antibody. After 10 hours of incubation, the level
of p53 progressively decreased until 24 hours had passed,
although it remained significantly higher (65%) than the level
measured at the beginning of the chase period. We think that
this reduction was a consequence of the degradation of p53,
which most likely prevailed over the production of immuno-
precipitable p53 in the second part of the experiment. These
considerations were supported by experiments in which cy-
cloheximide, an inhibitor of protein synthesis, was added with
-Rcl-2 -Bcl-2
FIGURE 9- Effects of apoptotic drugs on Bcl-2 content in Y79
cells, treated or untreated with insulin-like growth factor-I
(IGF-I). Y79 cells were grown for 24 hours in a serum-free
medium in the absence (A) or in the presence (B) of 10 ng/ml
IGF-I. Two micromolar camptothecin was added, and the in-
cubation continued for different periods. Cell extracts were
prepared, and identical amounts of protein were used for
western blot analysis. (A) Control cells (lane /); cell is treated
with camptothecin for 4 hours (lane 2), 8 hours (lane 3), or 24
hours (lane 4). (B) Control cells (lane 7); cells are treated with
camptothecin for 24 hours (lane 2).
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FIGURE 10. Effect of cycloheximide on the p53 level in Y79
cells cultured in the presence of topoisomerase inhibitors.
Extracts were prepared from Y79 cells treated for 24 hours
with 2 JAM camptothecin or 5 ̂ tM etoposide in the presence or
absence of 5 ju-M cycloheximide. (A) Western blot analysis. (B)
Densitometric analysis of p53 bands. Y79 cells cultured with-
out drugs (lanes 1, 2), with camptothecin (lanes 3, 4), or with
etoposide (lanes 5, 6). Five micromolar cycloheximide was
added to samples 2, 4, and 6.
camptothecin. Tn this case (Fig. 11C), the level of radioactive
p53 continued to increase beyond 10 hours of incubation and
at 24 hours, reached an increase of 140% compared with the
value measured at time 0. The results seem to indicate that the
addition of cycloheximide prevented p53 from degradation by
newly synthesized enzymes and showed that camptothecin
and etoposide stimulated processing of p53 during the entire
incubation period. When cycloheximide alone was added to
Y79 cells, no increase in the level of radioactive p53 was seen
(not shown).
Different results were obtained when labeled p53 was
immunoprecipitated by PAb421 antibody, which reacts with
an epitope (residues 371-380) that is present at the carboxyl-
terminal regulatory domain in human witd-type and mutant
p53- The intensity of the radioactive p53 band decreased dur-
ing the pulse-chase period in untreated (Fig. 1 IE) and treated
cells (Fig. 1 IF). In the latter case, however, the half-life of p53
was 11 hours, compared with 8 hours in control cells. The
relative intensities of p53 bands in cells treated with 2 /xM
camptothecin in comparison with p53 bands in control cells
are shown in Figure 11G.
DISCUSSION
The Effect of Camptothecin and Etoposide on
Apoptosis and on the Level of p53
In the present study, we showed for the first time that topo-
isomerase inhibitors can induce efficacious programmed cell
death in human retinoblastoma cells. This conclusion is sug-
gested by the appearance of morphologic features of apoptosis
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FIGURE 11. Pulse-chase analysis of p53 in Y79 cells treated with camptothecin. Cells were
pulse-labeled with 35S-methionine-35S-cysteine, as reported in the Methods section. Thereaf-
ter, the cells were incubated in complete Dulbecco's modified Eagle's medium, without
addition of drugs (A, E), with 2 JLLM camptothecin (B, F), or with 2 JUM camptothecin plus 5
l^M cycloheximide (C). Cells were harvested at time 0 (lane 7), 5 hours (lane 2), 10 hours
(lane 3), 15 hours (lane 4), and 24 hours (lane 5) of the chase period. Immunoprecipitation
of p53 was performed, as reported in the Methods section, using DO-1 (A, B, C, D) or PAb421
antibody (E, F, G). The immunoprecipitate proteins were resolved on 10% sodium dodecyl
sulfate-polyacrylamide gel and autoradiographed. The relative intensity of single p53 bands,
determined by densitometric analysis, is shown in D and G. The p53 level at time 0 was
considered to be 1. (D) ( • ) refers to A, ( • ) to B, and (A) to C. (G) (•) refers to E, and ( • )
refers to F.
that correspond to biochemical hallmarks of this process, such
as DNA fragmentation and nucleosomal enrichment. In our
studies, the most active compound was camptothecin; etopo-
side and amsacrine were effective at much higher concentra-
tions.
Treatment of Y79 cells with camptothecin or etoposide
induced a marked increase in p53 level. This effect, which was
evident after 4 hours of treatment, clearly anticipated the
induction of cell death.
It is well known that p53 protein, the product of a tumor-
suppressor gene, exerts an antiproliferative effect by inducing
an arrest in the cell cycle or apoptosis,17 two separate func-
tions of the protein. These events can be caused by means of
transactivation-dependent or -independent mechanisms. More-
over, it has been demonstrated that the level of p53 increases
in the cells as a consequence of DNA damage. Whether this
increase provokes cell cycle arrest or apoptosis is determined
by several factors, such as the amount of DNA damage, the
level of p53, and the availability of survival factors."36 Cells
with DNA damage should be eliminated in p53-dependent
apoptosis, when they are forced into a replicative cycle by
activated oncogenes.37 In particular, p53 is required for the
efficient activation of apoptosis after irradiation or treatment
with chemotherapeutic compounds such as 5-fluorouracil, eto-
poside, and adriamycin.18
p53 plays a deciding role in inducing apoptosis in cells
with no pRB, as has been suggested by Howes et al.38 They
demonstrated that p53 is required in apoptosis that has been
induced in the photoreceptor cells of transgenic mice by the
functional inactivation of pRB determined by the expression of
E7 protein. In line with this suggestion, Nork et al.39 have
provided evidence that, in human retinoblastoma, p53-immu-
noreactive cells are observed in close association with cells
undergoing apoptosis. Moreover, the involvement of p53 in
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apoptosis induced in retinoblastoma cell lines has been sug-
gested recently by Kondo et al.,40 who demonstrated the over-
expression of p53 and its associated protein WAF-1 after y-ra-
diation of the cells.
Our results demonstrate that the increase in p53 level,
which was induced by topoisomerase inhibitors, was corre-
lated to changes occurring at the amino-terminal domain of
p53. This conclusion is suggested by results of western blot
analysis or pulse-chase experiments performed using DO-1,
which specifically binds to an epitope located at this domain.
The increasing effect was not observed when we used PAb421
and PAb240, which bind to other epitopes. Our findings also
suggest that an amount of p53 was present in the Y79 cells in
a latent state and that treatment with topoisomerase inhibitors
induced the conversion of this form into a new form that was
immunoprecipitable by DO-1. Our results further indicate that
this effect was at least partially dependent on protein synthesis.
Many investigators have demonstrated that the activity of
p53 is regulated by several mechanisms at different levels.
Normal cells contain p53 protein in a latent state that can be
activated by UV radiation or by the intervention of highly
specific peptides.41'42 A transcriptionally inactive p53 form has
been seen in undifferentiated teratocarcinoma cells that un-
dergo p53-mediated apoptosis in response to DNA damage.43
Moreover, p53 is present in the cells as inactive complexes in
which it is associated with heat shock proteins,44 protein
kinases, and phosphatases.42 In a significant proportion of
human cancers, p53 is associated with MDM-2, a protein that
binds p53 and inhibits its transactivation activity.45
Currently, it is not possible to specify the mechanism by
which topoisomerase inhibitors induce the conversion in Y79
cells of the latent form of p53 to a form that is recognized by
DO-1. It has recently been suggested that genotoxic stress can
stimulate the processing of the latent form of p53. 46 Evidence
has been provided that p53 is sensitive to stress or DNA
damage through phosphorylation at its N terminus.47 In par-
ticular, it seems that topoisomerase-directed drugs are capable
of enhancing the level of the delta isoform of casein kinase-1.
This enzyme is involved in the phosphorylation of a group of
the sites at the N terminus of p534 8
The Effect of Camptothecin and Etoposide on the
Expression of p21, Bax, Insulin-like Growth
Factor-Binding Protein 3, and Bcl-2
Our results provide evidence that camptothecin and etoposide
induced the production of a new form of p53 that is transcrip-
tionally active. Treatment with both compounds increased the
level of p53 and the levels of three transcriptional targets of
this protein: p21, an antiproliferative factor, and Bax and IGF-
BP3, two apoptosis modulators. Furthermore, treatment with
topoisomerase inhibitors induced a concomitant reduction in
Bcl-2, a protein that promotes cell survival and inhibits apopto-
sis.3334 This effect took place after the increase in the p53
level, but it anticipated the increase in apoptosis. It therefore
seems possible that this effect may be a consequence of the
direct action of p53,49 although it is known that the expression
of Bcl-2 protein can also be regulated by other mechanisms that
are independent of p53 function.50
To obtain a better understanding of the mechanism by
which camptothecin and etoposide induce apoptosis in Y79
cells, it is necessary to analyze the role of the modulators that
seem to be involved in this process. It has been demonstrated
that p21 is responsible, at least partially, for the antiprolifera-
tive effect of p533 5 In many systems, p53 provokes a Gl arrest
by transactivating the expression of p21, which inhibits Gl
cyclin-dependent kinases, the enzymes involved in the phos-
phorylation of pRB. As a consequence, the pRB-E2F complex
cannot be broken down, and the cells are prevented from
entering the S phase of the cycle. In Y79 cells, which have no
pRB, the increase in p21 after treatment with apoptotic drugs,
indicates that this protein could be involved in another func-
tion that is still unknown.
Bcl-2 is a well known antiapoptotic factor51'52 that be-
longs to one of the most important classes of apoptosis-regu-
lating gene products, including proapoptotic and antiapoptotic
factors.33'34 Bax, a Bcl-2 family member that functions as a
proapoptotic factor, is capable of producing homodimers and
heterodimers with the cell death antagonists Bcl-2 and Bcl-X,.
The relative abundance of the Bcl-2 family of cell death agonists
compared with the number of antagonists determines the sus-
ceptibility of cells to an apoptotic stimulus. In Y79 cells,
topoisomerase inhibitors induce an increase in the expression
of Bax and a reduction in Bcl-2. Thus, the ratio of cell death
agonists to antagonists increases, and the cells become suscep-
tible to apoptosis.34
The Bcl-2 family acts at the level of the outer mitochon-
drial membrane as a regulator of intracellular ion fluxes and as
an inhibitor of the ICE-like proteases that are required for some
mechanisms of cell death.52 The reduction in Bcl-2 and the
concomitant increase in the level of agonist modulators in-
duces the activation of proteases that are involved in the
degradation of PARP.34'53 Our study demonstrates that treat-
ment of Y79 cells with topoisomerase inhibitors stimulated the
degradation of PARP with the appearance of an 85-kDa frag-
ment. It seems likely that this event in Y79 cells can also be
considered a consequence of the increase in the ratio of cell
death agonists to antagonists.
Antiapoptotic Role of Insulin-like Growth Factor-I
Results reported in this study suggest that IGF-I, aside from its
function in cell growth,6 is capable of opposing the apoptotic
effect of topoisomerase inhibitors. Moreover, our recent un-
published results show that aIR3, a monoclonal antibody ca-
pable of inhibiting the mitogenic activity of IGF-I,6 does not
modify the antiapoptotic effect exerted by the same com-
pound. Our results agree with the conclusions of Rubin and
Baserga54 and Sell et al.,55 who demonstrated that IGF-IR,
activated by its ligands, protects cells from apoptosis in vivo
and in vitro and that the domains of the IGF-I receptor required
for its antiapoptotic function are distinct from those required
for its proliferation or transformation.56
To explain the mechanism of the antiapoptotic action of
IGF-I in Y79 cells, we ascertained that IGF-I modified neither
the inhibitory effect exerted by camptothecin and etoposide
on the synthesis of DNA, nor their effect on the content of p53.
Instead, our results are consistent with a role for IGF-I in
regulating the level of Bcl-2, because treatment with IGF-I
protected Y79 cells from the reduction in Bcl-2 level induced
by camptothecin or etoposide. This conclusion agrees with the
recent observation of Singleton et al.57 that IGF-IR plays a role
in keeping Bcl-2 at a normal level.
It is interesting that p53 also mediates apoptosis by induc-
ing the production of IGF-BP3,31 a protein that has a high
affinity with IGF-I and interferes with IGF signaling. In the
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current study, treatment of Y79 cells with apoptotic drugs
markedly increased the level of IGF-BP3. This suggests that
through the production of this protein, the antiapoptotic ac-
tion of IGF-I can be controlled and its protective effect on the
expression of Bcl-2 can be removed.
Although the results described in this study are inconclu-
sive and many aspects deserve greater attention and further
experiments, the apoptotic mechanism of topoisomerase in-
hibitors in Y79 cells is partially evidenced by our results. Our
conclusion is that the drugs induce a reduction in Bcl-2 expres-
sion and an increase in that of p53. p53 stimulates, through a
transactivation mechanism, the expression of Bax protein.
Thus, among the members of the Bcl-2 family, the death-
agonist factors become prevalent, leading to the activation of
ICE-like activity with degradation of PARP. The growth of Y79
cells is stimulated by an autocrine mechanism dependent on
IGF-I and IGF-IR. IGF-I also exerts a clear antiapoptotic effect
that is most likely reduced by the increased expression of
IGF-BP3, induced by a transactivation mechanism dependent
on p53-
The Role of Apoptotic Drugs in Chemotherapy
for Retinoblastoma
Retinoblastoma is the most common intraocular neoplasm of
childhood. Treatment includes chemotherapy that is intended
to reduce tumor size and allow local treatment with photoco-
agulation, cryotherapy, or both. In this regard, the combination
of etoposide with carboplatinum is particularly efficacious.58
Intensive treatment with these compounds has been effective,
even in the advanced stages of tumor growth and in extraoc-
ular forms.59 Data in the present report suggest that the anti-
tumor action of etoposide could be a consequence of its
apoptotic effect. Our results also demonstrate that campto-
thecin is much more efficacious than etoposide in inducing
apoptotic death in Y79 cells. However, camptothecin and its
analogs are not yet used in the treatment of retinoblastoma.
We are currently investigating other compounds capable
of inducing death in retinoblastoma cells. Our recent results
demonstrate that cisplatin and carboplatin, whose apoptotic
action is well known,60'61 are effective in inducing cell death in
Y79 cells, although resistance occurs after prolonged treat-
ment (unpublished data, 1998). Other studies in progress in
our laboratory concerning sodium butyrate confirm that this
compound may induce differentiation22 or apoptosis23 in Y79
cells and that its apoptotic effect is independent of p53. Finally,
we have demonstrated the apoptotic effect induced by cer-
amide62 and by compounds that stimulate breakdown of sphin-
gomyelin (i.e., tumor necrosis factor and interleukin 1-J8). The
purpose of all these studies is to ascertain whether the admin-
istration of some of these compounds together with topoiso-
merase inhibitors can produce a clear apoptotic effect at min-
imal doses of camptothecin or etoposide.
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